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The visual system offers unparalleled precision in the assessment of neuroaxonal damage. With
the majority of patients with multiple sclerosis (MS) experiencing afferent and efferent visual
dysfunction, outcome measures capturing these deficits provide insight into neuroaxonal injury,
even in those with minimal disability. Ideal for use in clinical trials, visual measures are generally
inexpensive, accessible, and reproducible. Quantification of visual acuity, visual fields, visual
quality of life, and electrophysiologic parameters allows assessment of function, whereas optical
coherence tomography (OCT) provides reliable measures of the structural integrity of the
anterior afferent visual pathway. The technology of oculomotor biometrics continues to advance,
and discrete measures of fixation, smooth pursuit, and saccadic eye movement abnormalities are
ready for inclusion in future trials of MS progression. Visual outcomes allow tracking of neuro-
axonal injury and aid in distinguishing MS from diseases such as neuromyelitis optica spectrum
disorder (NMOSD) or myelin oligodendrocyte glycoprotein antibody–associated diseases
(MOGAD). OCT has also provided unique insights into pathophysiology, including the iden-
tification of foveal pitting in NMOSD, possibly from damage to Müller cells, which carry an
abundance of aquaporin-4 channels. For some study designs, the cost-benefit ratio favors visual
outcomes over more expensive MRI outcomes. With the next frontier of therapeutics focused on
remyelination and neuroprotection, visual outcomes are likely to take center stage. As an in-
ternational community of collaborative, committed, vision scientists, this review by the In-
ternational MS Visual System Consortium (IMSVISUAL) outlines the quality standards,
informatics, and framework needed to routinely incorporate vision outcomes into MS and
NMOSD trials.
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The first revolution in ophthalmology occurred in 1845 with
the invention of the ophthalmoscope. Before this time, there
was no clear way to differentiate visual disorders; diseases
were categorized only as either ophthalmia or blindness.1
Progress was made into the early 20th century when optic
neuritis (ON) was distinguished from other forms of optic
disc swelling and linked to MS.1 A century later, we now have
tools that visualize retinal damage to 5–6 μm resolution and
hold strong promise as outcome measures for clinical trials.
At least 50% of patients with MS experience ON during the
course of their disease, with many more experiencing sub-
clinical damage to retinal ganglion cells.2 Up to 70% will also
experience efferent dysfunction from oscillopsia to subtle
smooth pursuit dysfunction and impaired gaze stabilization.2
In neuromyelitis optica spectrum disorders (NMOSDs),
nearly half of patients may have a risk of developing clinical
blindness in the first 5 years of disease.3 Recently, myelin
oligodendrocyte glycoprotein antibody–associated disease
(MOGAD) has emerged as pathophysiologically distinct
from classic NMOSD with an even stronger preponderance
for optic nerve involvement.
The visual system is highly amenable to quantification, with
well-understood structure-function relationships, and yet it
has been underutilized in clinical trials. Rigorous methods
have recently emerged to quantify visual injury in neuro-
inflammatory diseases. Herein, the International MS Visual
System Consortium (IMSVISUAL) (imsvisual.org) reviews
structure-function relationship and utility in clinical trials of
both afferent and efferent visual system outcome measures
that have—in light of relatively low costs, high reliability, and
exquisite sensitivity for pathology—the potential to transform
the next generation of MS, NMOSD, and MOGAD clinical
trials.
Afferent Visual System Anatomy
Retinal ganglion cells (RGCs) represent the anterior visual
pathway and are affected by inflammation, demyelination, and
neuroaxonal degeneration during ON or subclinical optic
neuropathy (Figure 1A). RGC axons track along the inner
retinal nerve fiber layer (RNFL) and converge at the optic
nerve head (ONH) to form the optic nerve. RGC cell bodies
are in the retinal ganglion cell layer (GCL). Subjacent to the
GCL, the inner nuclear layer (INL) may also be affected by
neuroimmunologic diseases.4,e1-e5 Minimal changes in outer
retinal layers have been reported after ON but may be tran-
sient5 or specific to progressive forms of MS.6 Nonneuronal
retinal cells have not been as well studied, but astrocyte re-
activity plays a crucial role in neuroimmunologic disease, es-
pecially in NMOSD, and advancing metrics targeting these
cell types are of interest.7
Beyond the cribriform plate, the optic nerve is myelinated and
travels approximately 4 cm to the optic chiasm, where the
axons from the contralateral nasal and ipsilateral temporal
hemiretinas join to form the optic tract (OT). Lesions that
involve the chiasm or OT8 are more common in aquaporin-4
(AQP4)-IgG+ NMOSD than in MS, and longitudinally ex-
tensive intraorbital optic nerve involvement is more frequent
in MOGAD than in AQP4-IgG+ NMOSD.e6 The OT carries
visual signals through the dorsal thalamic lateral geniculate
nucleus (LGN) and secondary LGN neurons within the optic
radiation (OR) to the primary visual cortex (Figure 1B).
Anterograde and retrograde transsynaptic degeneration can
occur across the synapse in the dorsal LGN9e7 and is of in-
terest in the context of visual outcome measures in trials. The
primary visual (calcarine/striate) cortex is organized into
columns in which neurons are grouped according to their
function. The occipital cortical thickness reflects this complex
cytoarchitecture, and this thickness can be captured with MRI
surface-based cortical reconstruction.e8 From the primary vi-
sual cortex, there are projections to the parietal (dorsal
pathway for visually guided movements) and temporal lobes
(ventral pathway for object recognition) (Figure 1B). The
extrastriate occipital cortex also has areas with functional
specificity that may be involved in neuroplasticity recovery
processes after ON.e9
Afferent Visual Function Measures
An array of tools captures complementary measures of affer-
ent visual function. These include assessments of visual acuity,
Glossary
AQP4 = aquaporin-4; CS = contrast sensitivity; EDSS = Expanded Disability Status Scale; EDTRS = Early Treatment Diabetic
Retinopathy Study; ERGs = Electroretinograms; GCIPL = ganglion cell + inner plexiform layer; GCL = ganglion cell layer;
HCVA = High-contrast visual acuity; IMSVISUAL = International MS Visual System Consortium; INL = inner nuclear layer;
ISCEV = International Society for Clinical Electrophysiology of Vision; LCLA = low-contrast letter acuity; LGN = lateral
geniculate nucleus; MD = mean deviation; MOGAD = myelin oligodendrocyte glycoprotein antibody–associated disease;
MSFC = MS Functional Composite; NEI-VFQ = National Eye Institute Visual Function Questionnaire; NMOSDs =
neuromyelitis optica spectrum disorders;OCT = optical coherence tomography;ON = optic neuritis;ONH = optic nerve head;
ONL = outer nuclear layer; OPL = outer plexiform layer; ONTT = optic neuritis treatment trial; OR = optic radiation; OT =
optic tract; QoL = quality of life; RGC = Retinal ganglion cells; RNFL = retinal nerve fiber layer; VEPs = Visual Evoked
Potentials.
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formal perimetry, electrophysiology, and self-reported visual
quality of life (QoL). Key to applying these measures is rec-
ognizing that the magnitudes of deficits are expected to be
different in eyes with prior ON vs subclinical injury. Consis-
tent across most clinical trials has been the application of the
ON diagnostic criteria used in the optic neuritis treatment
trial (ONTT).e10
High- and Low-Contrast Visual Acuity in ON
and MS
High-contrast visual acuity (HCVA), black letters on a white
background, is part of the visual functional system score in the
Expanded Disability Status Scale (EDSS). Standardized
HCVA tools include the 100% Early Treatment Diabetic
Retinopathy Study (ETDRS) charts (Precision Vision, La
Salle, USA) and Snellen Charts. Methods that generate con-
tinuous variables amenable to statistical models (letters cor-
rect, logMAR, and decimal vision scores) are preferable for
clinical trials. A clinically meaningful change in HCVA is
generally accepted as a minimum 5-letter difference.e11
A normal HCVA result, however, does not exclude MS-
related optic nerve injury.10 Low-contrast vision assessments
are more sensitive and include measures of contrast sensitivity
(CS) and low-contrast letter acuity (LCLA). In the former,
the patient is asked to read letters of constant size but de-
creasing contrast to determine the CS threshold. In the
ONTT, CS determined by the Pelli-Robson Chart11 dem-
onstrated greater sensitivity to detect visual injury than
HCVA.12 For LCLA, the level of contrast is held constant and
the letters decrease in size, similar to how HCVA is measured,
but instead of 100% black on white contrast, light gray colors
are used (e.g., 2.5% or 1.25% contrast). The Sloan low-
contrast chartse12 have been frequently used to provide LCLA
measurements, but other tools are also available. As an ex-
ample, the standardized low-contrast Landolt C Broken Rings
Chart (at 3 M) with direct data entry into an electronic data
capture system was used for visual outcomes in the
N-Momentum trial of inebilizumab (NCT02200770) in
NMOSD. As the level of contrast required for letter per-
ception is affected by letter size,e13-e14 the Sloan LCLA may
be more sensitive than CS in detecting subtle losses.13
Furthermore, Sloan LCLA correlates strongly with optical
coherence tomography (OCT), electrophysiologic, brain
imaging, and self-reported QoL outcomes.13 Conse-
quently, Sloan LCVA has been proposed as a primary
outcome measure for visual function in ON, MS, and
NMOSD and recommended as a potential (4th) compo-
nent of the MS Functional Composite (MSFC) scale of MS
disability.13 A seven-letter loss in LCVA has been validated
as clinically meaningful.e13 LCVA is the primary outcome
for an ongoing trial of nanocrystalline gold as a remyeli-
nating agent (NCT03536559).
For assessment of neurologic acuity deficits, it is critical to
address confounding refractive error. Ideally, a formal re-
fraction and lens correction is performed; however, correction
with pinhole devices has also been accepted. Assessments
should be performed under standard lighting conditions
throughout a trial.
Digital tools created to capture both HCVA and LCLAe15-e16
may have challenges with backlighting on devices, but these
tools can provide standardization across trial sites (less issue
with ambient lighting in traditional testing), allow home use,
and ease data collection processes.
Visual Fields
Substantial visual deficits may be missed if outcomes focus on
central acuity measures alone. In MS, NMOSD, and MOGAD,
VF defects may vary, but a diffuse central scotoma is most
commonly observed in acute ON.14 After recovery, patients may
Figure 1 Afferent Visual System Anatomy
(A) Phototransduction occurs in photoreceptor cells in the outer retina. These visual signals are processed and transmitted by horizontal and bipolar cells
residing in the inner nuclear layer (INL). Bipolar cell axons form synapses with the dendrites of retinal ganglion cells (RGCs) in the inner plexiform retinal layer.
The optic nerve is formed by the unmyelinated axons of RGCs, tracking along the inner retinal surface in the nerve fiber layer (RNFL) and converging at the
optic nerve head. Subjacent to the ganglion cell layer (GCL), the INL consists of the bipolar, horizontal, and amacrine cells as well the cell bodies of astrocytic
Müller cells. (B) Beyond the cribiform plate, the RGC axons of the optic nerve are myelinated and travel approximately 4 cm to the optic chiasm. The optic
nerve partially decussates at the chiasm: The axons from the contralateral nasal and ipsilateral temporal hemiretinas join to form the optic tract (OT). The OT
carries visual signals to the thalamic lateral geniculate nucleus (LGN). The secondary LGN neurons project to the primary visual cortex through the optic
radiations (OR). From the primary visual cortex, projections go through the extrastriate cortex of the occipital lobe to the parietal lobe (the dorsal pathway for
visually guided movements) and the temporal lobe (the ventral pathway for object recognition). Parts of the figure are provided by courtesy of neurodial.de
(neurodial.de/2017/08/25/schematic-figure-retina-creative-commons-license/).
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show an arcuate scotoma due to the predominant temporal loss
of retinal nerve fibers and ganglion cells.14 VF defects are not
limited to optic nerve patterns and may include those consistent
with injury to the optic chiasm, optic tract, optic radiations, or
occipital lobe.
VF can be assessed with different techniques. Standard static
automated perimetry evaluates the central 10–30 degrees of
vision and provides a qualitative depiction of field loss pattern
and 2 quantitative indices: the mean deviation (MD), which
measures the sensitivity deviation at each test location from
the age-adjusted healthy population, and the pattern SD
(PSD), which is the average sensitivity deviation from the
normal slope after correction for global sensitivity differences.
Kinetic perimetry can be used in patients with difficulty fo-
cusing or those with expected peripheral field loss, but
quantification of results can be challenging for clinical trials.
VF interpretation can be limited because of defect variability,
severely impaired VA, or impaired cognition. Standardization
can be reached in trials by defining light conditions and pre-
defining cutoffs for loss of fixation frequency, false nega-
tives, and false positives.15 In acute ON, automated perimetry
has been successfully used as a primary outcome as in the
ONTT12,15 and in a recent NMO trial (Table 1).16 For trials
using acute ON as a model for remyelination and neuro-
protection, perimetry has been used as a secondary out-
come.e16-e18
Electrophysiology
Across electrophysiology methods, recordings are dependent
on stimulus parameters, the patient’s anatomy, and the testing
environment. To differentiate true signal from electrical back-
ground potentials, signal amplification and averaging tech-
niques are used. When using electrophysiologic outcomes for
clinical trials, clear and standardized protocols are essential.e19
Visual Evoked Potentials
Visual Evoked Potentials (VEPs) have been successfully used
as outcomes in trials for acute ON orMS-related chronic optic
neuropathy (Table 2, eTable 1, links.lww.com/NXI/A675).
They are electrical potentials generated in the occipital cortex
(captured with occipital electrodes) in response to visual
stimuli.e19 As VEPs are hidden in EEG signals, they are
evaluated with averaged waveform signals from repetitive
stimulation. For quality control, the International Society for
Clinical Electrophysiology of Vision (ISCEV) standards
should be applied. A variety of stimulation paradigms may be
used. Flash VEPs (using bright-light stimuli) have been shown
to be inferior to pattern-reversal VEPs (using mostly check-
erboard stimuli) and are reserved for patients unable to fixate
or with severe central vision loss (e.g., NMOSD-ON).e19
Pattern-reversal (or full-field) VEP analysis is based on the
first major positive deflection of the signal waveform, which
occurs approximately 100 ms after the stimulus (P100
latency).e19 This latency reflects conduction speed andmyelin
integrity. The upper P100 latency limit of normal differs
according to the reference population and VEP method, and
values should always be interpreted within the context of the
individual, taking previous and contralateral eye measure-
ments into account. The P100 amplitude peak is more vari-
able than latency and should be used with caution in clinical
trials, but it may help differentiate demyelinating ON from
noninflammatory/ischemic optic neuropathies.e19
During acute demyelinating ON, the P100 latency is typically
delayed (>125ms) and the peak amplitude reduced. In cases of
severe vision loss (central acuity <20/100–20/200), the patient
may be unable to fixate to complete a pattern-reversal VEP, or
the response may be absent.e20 For this reason, it is challenging
to measure correlation between VEP and visual acuity during
an acute episode of ON. With remittance of the ON, the am-
plitude recovers, and the latency may slowly shorten over
weeks to 2 years.16 Latency improvement is most pronounced
in the first 3–6 months with decreasing inflammation and
presumed early remyelination. Lack of latency recovery or in-
sidious worsening of latency delay is associated with overall
disability.e21-e23 Latency insidious worsening in ON or non-
ON eyes may indicate chronic global demyelination without
sufficient remyelination.17,18 In recovered ON or non-ON MS
eyes, correlations between LCLA and VEP latency are ob-
servable in cross-sectional analyses.e24
Given the changes of VEP latencies over time following ON, the
timing of when to measure VEPs in a clinical trial requires
consideration of the intervention and desired effect/outcome.
For remyelinating therapies, given the lack of a widely accepted
gold standard for MRI-based myelin measurements, P100 la-
tency has been prominent as a primary or secondary outcome
measure.19 Two recent trials using VEP as the primary outcome
for remyelination interventions demonstrated greater P100 la-
tency reduction by clemastine in chronicMS optic nerve injury19
and by liothyronine sodium in an acute ON model.20 Other
potential remyelinating or neuroprotective agents showed neg-
ative VEP results for treatment effects, including the phase 2 trials
of anti–LINGO-1 antibodies21 and phenytoin.22 Advancement in
the basic science of evoked potentials and several ongoing trials
with remyelinating therapies (NCT03586557, NCT03605238,
NCT03062579,NCT01883661,NCT01364246,NCT02671682,
NCT01337986,NCT04042363,NCT04002934,NCT03774407,
and NCT04121468) will enlighten and continue to improve the
application of VEP for clinical trials.
Electroretinograms
Electroretinograms (ERGs) recorded from the cornea or per-
iorbital skin capture electrical potentials generated in the reti-
na.e19 For flash ERGs, the first negative (consisting of rod
and cone photoreceptor cell signals; ca. 14 msec) and positive
(b-wave consisting of the slower bipolar cell signals; ca. 30–35
msec) waveform deflections are evaluated.e19 In contrast, a
pattern ERG records the response to a pattern-reversal stim-
ulus (e.g., alternating checkerboard); the resulting b-wave
(N95; ca. 95 msec) is suggested to reflect the activation of
RGCs.e19 In MS and NMOSD—especially but not exclusively
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after ON—N95 is prolonged, and the amplitude is diminished,
indicative of retinal damage.23,e25-26 A novel ERG protocol
recently identified b-wave changes in AQP4-IgG–seropositive
NMOSD in line with Müller glial dysfunction, suggesting a
potential relevance of ERG for differential diagnosis and trial
outcome parameters in NMOSD.7
Multifocal VEP and ERG
Multifocal VEP and ERG approaches divide the visual field
into sectors, which are stimulated and assessed separately.e27-28
The waveforms are comparable to those of full-field ap-
proaches, and multifocal methods are objective alternatives to
VF measurements.e29 However, a high demand for patient
Table 1 Clinical Trials and Interventional Studies Using Visual Fields as an Outcome Measure
Trial (Number/name; publication) Patients Drug VF outcome Effect on VF
Visual recovery in the acute phase optic neuritis
NCT00000146 (ONTT; Beck et al. Arch Ophthal
1993; 111: 773–775)
457 Methylprednisolone + oral
prednisone vs oral prednisone vs
placebo
Primary Accelerated visual recovery at
6 mo in the
methylprednisolone group.
No intergroup difference in
visual recovery at 12 mo.
Not registered (Merle H et al., Arch
Ophthalmol 2012; 130: 858–862)
36 (NMO) Plasma exchange +
methylprednisolone vs
methylprednisolone
Primary Significant effect (p = 0.02)
NCT04155424 15 (pediatric
NMOSD)
Eculizumab (open label) Secondary Ongoing
Visual recovery in the chronic phase of optic neuritis
NCT01337986 53 Dalfampridine vs placebo Secondary Significant effect (p = 0.04)
NCT02220244 (Tourbah A et al., CNS Drugs
2018; 32: 661–672)
93 MD1003 vs placebo Secondary No significant effect
NCT01274702 (VISION; Schinzel J et al., Trials
2012; 13)




NCT04148781 (FAMP-ON) 20 Fampridine (open label) Primary Ongoing
Neuroprotection in acute ON
NCT00355095 (Sühs KW et al., Ann Neurol
2012; 72: 199–210)
40 Erythropoietin vs placebo Secondary No significant effect
Not registered (2012 Esfahani MR et al.,
Graefes Arch Clin Exp Ophthalmol. 2012 Jun;
250(6):863–9)
50 Memantine vs placebo Secondary No significant effect
NCT01294176 (Falardeau J et al., Mult Scler J -
Exp Transl Clin 2019; 5: 205521731985019)
31 Lipoic Acid vs placebo Secondary No significant effect
(incomplete recruitment)
NCT01802489
(ACTION; McKee JB et al., BMJ Open 2015; 53) 46 Amiloride vs placebo Secondary Ongoing
NCT01962571 (TONE; Diem R et al., BMJ Open
2016; 6)
100 Erythropoietin vs placebo Secondary Ongoing
NCT04042363 (ONSTIM) 45 Active transorbital electrical




NCT03862313 (ACSON) 30 Repetitive transorbital alternating
current stimulation vs sham
stimulation (control intervention)
Secondary Ongoing
EudraCT: 2020-003147-29 (NCT # pending) 36 ACT-01 vs placebo Primary Ongoing
Neuroprotection in multiple sclerosis
NCT00395200 (Connick P et al., Lancet Neurol
2012; 11: 150–156)
10 (SPMS) Autologous mesenchymal stem
cells (open label)
Secondary No significant effect
Abbreviations: ONTT = optic neuritis treatment trial; NMOSD = neuromyelitis optica defined in the study by the presence of anti–aquaporin-4 antibodies;
NMOSD = neuromyelitis optica spectrum disorder defined in the study by the 2015 Criteria; SPMS = secondary progressive MS.
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Table 2 Electrophysiologic and MRI Outcomes in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder
(NMOSD) Clinical Trials
Trial (Trial name,
patients) Drug/treatment VEP measures Imaging measure
NCT00355095
40 (acute ON)
Erythropoietin (33000IU IV for 3 days)
vs placebo
Secondary (change in ffVEP latency and
amplitude)
Improved latency in intereye analysis (p < 0.001),
no effect on amplitude
Optic nerve volume: no change over 16 wks
NCT00261326 (10)
64 (acute ON)
Simvastatin (80 mg) vs placebo Secondary (change in ffVEP P100 latency and
amplitude)
Effect on VEP latency (p = 0.0132) and VEP
amplitude (p = 0.0103)










Nerispirdine (50 mg or 400 mg) vs
placebo
Primary (ffVEP P100 latency)—ongoing —
NCT03350633144
118 (NMOSD)
Tocilizumab vs azathioprine Exploratory (change in P100 latency and
amplitude change over 60 wks)
P100 latency increased compared with those in
the tocilizumab group (p = 0.009)





Corticosteroid and plasma exchange
vs corticosteroids alone




60 (MS or CIS)
Immunoabsorption vs
plasmapheresis




Cross-over trial for clemastine
fumarate (4 mg) vs placebo
Primary (change in ffVEP P100 latency)
Reduced P100 latency delay by 1.7 ms/eye
(p = 0.0048)
DTI: secondary–white matter FA—no effect




RCT clemastine 12 mg and 8 mg vs
placebo





100 mg/kg IV) vs placebo
Primary (change in ffVEP P100 latency)—no
significant differences
T2 lesion activity: T2 and enhancing lesions
recorded—no difference between groups
NCT01864148
(SYNERGY)100
Anti–LINGO-1 vs placebo in RRMS T2 lesion activity: exploratory—new or
enhancing T2 lesions
DTI: subgroup—improved disability
outcomes in 10 mg/kg group if lower
baseline DTI-RD
MTR : exploratory. In post hoc analysis of 10




Phenytoin (4 mg/kg) vs placebo Primary (change in ffVEP P100 latency and
amplitude)—no significant differences
T2 lesion activity: Secondary—optic nerve
lesion length—no difference





Cross-over trial for dalfampridine
(10 mg) vs placebo













Delayed start trial bazedoxifene
acetate (40 mg) vs placebo + late
bazedoxifene acetate





CNM-Au8 (15 mg or 30mg) vs placebo Secondary (ffVEP and mfVEP latency)—ongoing T2 lesion activity: secondary—new or
enhancing T2 lesions
Continued
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Table 2 Electrophysiologic and MRI Outcomes in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder
(NMOSD) Clinical Trials (continued)
Trial (Trial name,




Delayed start trial for metformin (500
mg/m2/day) vs placebo





Amiloride (10 mg) vs placebo Secondary (differences in ffVEP and pattern ERG)
VEP latency prolonged in the amiloride group





Erythropoietin (33000IU IV for 3 days)
vs placebo
Secondary (change in ffVEP latency and
amplitude)
Improved latency in intereye analysis (p < 0.001),
no effect on amplitude
Optic nerve volume: no change over 16 wks
NCT00261326 (10)
64 (acute ON)
Simvastatin (80 mg) vs placebo Secondary (change in ffVEP P100 latency and
amplitude)
Effect on VEP latency (p = 0.0132) and VEP
amplitude (p = 0.0103)










Nerispirdine (50 mg or 400 mg) vs
placebo
Primary (ffVEP P100 latency)—ongoing —
NCT03350633144
118 (NMOSD)
Tocilizumab vs azathioprine Exploratory (change in P100 latency and
amplitude change over 60 wks)
P100 latency increased compared with those in
the tocilizumab group (p = 0.009).





Corticosteroid and plasma exchange
vs corticosteroids alone




60 (MS or CIS)
Immunoabsorption vs
plasmapheresis




Cross-over trial for clemastine
fumarate (4mg) vs placebo
Primary (change in ffVEP P100 latency)
Reduced P100 latency delay by 1.7 ms/eye
(p = 0.0048)
DTI: secondary—white matter FA—no effect




RCT clemastine 12 mg and 8 mg vs
placebo





100 mg/kg IV) vs placebo
Primary (change in ffVEP P100 latency)—no
significant differences
T2 lesion activity: T2 and enhancing lesions
recorded—no difference between groups
NCT01864148
(SYNERGY)100
Anti–LINGO-1 vs placebo in RRMS T2 lesion activity: exploratory—new or
enhancing T2 lesions
DTI: subgroup—improved disability
outcomes in 10 mg/kg group if lower
baseline DTI-RD
MTR: exploratory. In post hoc analysis of 10




Phenytoin (4 mg/kg) vs placebo Primary (change in ffVEP P100 latency and
amplitude)—no significant differences
T2 lesion activity: secondary—optic nerve
lesion length—no difference





Cross-over trial for dalfampridine
(10 mg) vs placebo









Primary (change in ffVEP P100 latency)—ongoing —
Continued
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alertness and fixation as well as issues of intersubject variability,
especially formultifocal VEP (mfVEP), has been limiting. Newer
stimulation and analysis algorithms may provide a better stan-
dardization and user friendliness. These mfVEP devices have
been used in a subanalysis of the anti–LINGO-1 remyelination
clinical trial24 and are currently used as in an ongoing study
investigating the effects of nanocrystalline gold to treat remye-
linating failure (NCT03536559). Multifocal ERG responses
have been studied in MS and NMOSD,31 albeit without appli-
cation in neuroimmunology clinical trials.
Additional Measures
Other afferent measures include the analog and digital flicker
tests, object from motion (OFM), and critical flicker fre-
quency (CFF). Digital administration may expand the ac-
cessibility of new visual outcomes for trials. As an example, the
digital Aulhorn flicker test showed superior diagnostic sensi-
tivity (sensitivity 93% and specificity 96%) compared with the
Aulhorn analog flicker test (sensitivity 76% and specificity
100%).e32 The digital CFF test associates with disability
in patients with MS.e33 OFM generates a hidden object that is
Table 2 Electrophysiologic and MRI Outcomes in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder
(NMOSD) Clinical Trials (continued)
Trial (Trial name,




Delayed start trial bazedoxifene
acetate (40 mg) vs placebo + late
bazedoxifene acetate










Delayed start trial for metformin (500
mg/m2/day) vs placebo





Amiloride (10 mg) vs placebo Secondary (differences in ffVEP and pattern ERG)
VEP latency prolonged in the amiloride group





Erythropoietin (33000IU IV for 3 days)
vs placebo
Secondary (change in ffVEP latency and
amplitude)
Improved latency in intereye analysis (p < 0.001),
no effect on amplitude
Optic nerve volume: no change over 16 wks
NCT00261326 (10)
64 (acute ON)
Simvastatin (80 mg) vs placebo Secondary (change in ffVEP P100 latency and
amplitude)
Effect on VEP latency (p = 0.0132) and VEP
amplitude (p = 0.0103)










Nerispirdine (50 mg or 400 mg) vs
placebo
Primary (ffVEP P100 latency)—ongoing —
NCT03350633 144
118 (NMOSD)
Tocilizumab vs azathioprine Exploratory (change in P100 latency and
amplitude change over 60 wks)
P100 latency increased compared with those in
the tocilizumab group (p = 0.009).





Corticosteroid and plasma exchange
vs corticosteroids alone




60 (MS or CIS)
Immunoabsorption vs
plasmapheresis




Cross-over trial for clemastine
fumarate (4 mg) vs placebo
Primary (change in ffVEP P100 latency)
Reduced P100 latency delay by 1.7 ms/eye
(p = 0.0048)
DTI: secondary—white matter FA—no effect




RCT clemastine 12 mg and 8 mg vs
placebo




Anti–LINGO-1 mAb (BIIB033, 100 mg/
kg IV) vs placebo
Primary (change in ffVEP P100 latency)—no
significant differences
T2 lesion activity: T2 and enhancing lesions
recorded—no difference between groups
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perceived through motion detection and can be used to assess
de/remyelination.e34 These tests, while not yet in trials, may
hold promise for use in future designs.
Vision QOL
Although patients with MS rate visual function as a top
concern,25 vision-related patient-reported outcomes have
been widely neglected in pivotal trials of MS immunother-
apy.e35 Visual QoL in both MS and NMOSD correlates with
LCLA and structural measures of retinal damage.26-28 The
commonly used 51-item National Eye Institute Visual Func-
tion Questionnaire (NEI-VFQ) comprises 12 individual sub-
scales for general health, general vision, ocular pain, near
activities, distance activities, driving, color vision, peripheral
vision and vision-specific social functioning, mental health, role
difficulties, and dependencies. A final composite score is gen-
erated by averaging all subscale scores except the general health
item. An additional version with 39 and 25 items and a neuro-
ophthalmic supplement have since been established and have
been applied to measure vision-related QoL in MS.29,30 Use of
the NEI-VFQ with the neuro-ophthalmic supplement would
be recommended for neuroimmunology trials.
Afferent Visual System
Structural Measures
Optical Coherence Tomography (OCT)
Peripapillary and Macular Measurements
OCT uses light waves passing through the pupil, vitreous, and
retinal layers and then reflecting off the pigmented retinal
epithelium to reconstruct images of the retina and assess tis-
sue integrity. Over the past 20 years, studies describing OCT
outcomes in MS, NMOSD, and MOGAD have exponentially
increased.31 Initial work used time-domain OCT, whereas
recent studies have leveraged the faster acquisition speeds,
higher-resolution images (axial resolution 4–6 μm), and im-
proved reproducibility of spectral domain OCT.e36-e37 Seg-
mentation of the images, typically performed using automated
algorithms, allows the quantitative assessment of discrete
retinal neuronal and axonal layers (Figure 2). With appro-
priate quality control in acquisition,32 these quantitative
measures demonstrate excellent test-retest reliability, a critical
feature for clinical trial outcomes.33
MS, NMOSD, and MOGAD observational OCT studies have
largely focused on the macular ganglion cell + inner plexiform
layer (GCIPL) and peripapillary RNFL (pRNFL) thickness,
representing the integrity of RGC cell bodies and axons, re-
spectively. Following acute ON, there is rapid thinning of the
GCIPL, often within the first month of onset, and this process is
largely completed by 3 months.34,35 The pRNFL frequently ex-
hibits increased thickness during acuteONdue to swelling, which
confounds the baseline measurement and leads to a delayed time
course of detecting atrophy of the pRNFL compared with the
GCIPL.34,35 It is best tomeasure pRNFL6months after onset for
assessment of axonal loss from an acute ON event.34,35
Selecting the specific OCT outcome for a trial depends on the
disease state and time course of interest (Table 3). Important
considerations for incorporating OCT measures in trials of
putative neuroprotective agents in acute ON include the
following: 1) GCIPL thickness is superior to pRNFL thick-
ness at early time points, given the lack of swelling at baseline,
2) GCIPL thinning occurs rapidly during the first month after
ON, and participants should be enrolled shortly after symptom
onset; very early intervention (within 2–4 weeks) with thera-
peuticsmay be required to change the outcome,36 3) a 6-month
trial duration could be sufficient to detect a difference in
GCIPL or pRNFL thinning between treatment groups (though
Figure 2 Optical Coherence Tomography Peripapillary and Macular Measurements
Upper left: Fundus image with superimposed macular
GCIPL thickness map. Bottom: Horizontal macular OCT
B-scan traversing the fovea, corresponding to the red
horizontal line shown in the fundus photograph (upper
left). The scan has been automatically segmented
(boundaries between retinal layers are outlined in red).
Upper right: Peripapillary RNFL ring scan; the shown
OCT B-scan shown corresponds to the purple peri-
papillary ring shown superimposed on the fundus im-
age. RNFL = retinal nerve fiber layer; GCIPL = ganglion
cell + inner plexiform layer; INL = inner nuclear layer;
OPL = outer plexiform layer; ONL = outer nuclear layer.
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should consider if investigative medication could alter typical
time course of retinal layer thinning).
Consistent with postmortem findings,e2 pRNFL and GCIPL
thicknesses are lower than in the healthy population even in those
without a history of clinical ON, but thinning is more severe
in ON eyes.37 The etiology of insidious optic nerve injury in MS
is not fully understood but may have contributions from sub-
clinical optic nerve inflammation or transsynaptic retrograde de-
generation from posterior visual pathway injury. Compared with
MSON eyes, eyes with AQP4-IgG andMOGAD-associated ON
have greater pRNFL and GCIPL thinning, which appears to be
commensurate with greater losses in HCVA and LCLA in AQP4-
IgG, but notMOG-IgG, associatedON.38While not as prominent
as in MS, there is some evidence to suggest that subclinical
retinal neuroaxonal loss may occur in NMOSD, possibly
caused by an attack-independent astrocytopathy.e4, e38-e41
Consistent with this, attack-independent tissue loss and
associated functional changes were found in the parafoveal
region, which is rich in astrocytes and AQP4-expressing
Müller cells.7,e40-e42
Accelerated rates of inner retinal atrophy in MS eyes are
associated with inflammatory disease activity, global disability
progression, and increased brain atrophy.6,39,e43-e44 Disease-
modifying therapies (DMTs) may differentially affect pRNFL
and GCIPL thinning in MS, mainly in the relapsing-remitting
stage.40 Important to trial design, there are floor effects in eyes
that have already had significant retinal injury. This is in part
why one might consider adjusting for baseline OCT values,
even in randomized trials. Also relevant for study design and
inclusion criteria, the proportion of pRNFL and GCIPL
thinning attributable toMS decreases with older age. After age
65 years, >80% of the rate of thinning in these layers is at-
tributable to normal aging.6 pRNFL and GCIPL thinning is
faster earlier in the RRMS disease course (when there is more
tissue to lose), whereas progressive disease subtype (which is
associated with older age) is independently associated with
faster inner retinal layer thinning.6 Normative values of retinal
layer thicknesses differ by race, with African American pa-
tients with MS exhibiting faster rates of retinal atrophy.41,e45
Differential effects of sex on levels of retinal injury exist, with
men and boys demonstrating worse atrophy after ON.42,43
These data highlight the importance of accounting for patient
demographics on rates of pRNFL/GCIPL thinning when
designing trials.
In addition to pRNFL and GCIPL, deeper retinal neuronal
layers have been proposed as biomarkers of chronic neuro-
degeneration, with accelerated INL and ONL atrophy
Table 3 Summary Recommendations for Application of Visual Outcome Measures for Multiple Sclerosis (MS) and
Neuromyelitis Optica Spectrum Disorder (NMOSD) Trials Based on the Study Design
Visual outcome
measure Traditional DMT trials
Acute ON neuroprotection or
remyelination trials
Chronic injury neuroprotection or
remyelination trials
HCVA Best-corrected monocular HCVA should be
collected at baseline and follow-up visits
Capture HCVA at visual nadir and recovery
values at 3, 6, and/or 12 mo.
Best-corrected monocular HCVA should be





Best-corrected monocular LCLA should be
collected at baseline and follow-up visits. CS
also appropriate, but LCLA may be more
sensitive to change over time.
Capture LCLA or CS at visual nadir and
recovery values at 3, 6, and/or 12 mo.
Best-corrected monocular LCLA should be
collected at baseline and follow-up visits. CS
is also appropriate, but LCLA may be more
sensitive to change over time.
VF perimetry May not have as high utility in this design. Capture perimetry at visual nadir and
recovery values at 3, 6, and/or 12 mo.
Assess data quality and ability to fixate
(may be impaired in severe ON).
May not have as high utility in this design.
VEP, mfVEP May not have as high utility in this design. Capture VEP or mfVEP at visual nadir and
recovery values at 3, 6, and/or 12 mo.
Assess data quality and ability to fixate
(may be impaired in severe ON).
Capture VEP or mfVEP at baseline and all
follow-up visits. Assess data quality and
ability to fixate (may be impaired in eyes
with a history of severe ON).
OCT Obtain spectral domain imaging at baseline
and semiannual or annual follow-up visits,
capturing pRNFL, total macular volume, and
automated retinal layer segmentation
outcomes. Account for history of and new
events of ON during study, as well as baseline
OCTvalues. Adhere toOSCAR-IB criteria68 and
APOSTEL recommendations127
Obtain spectral domain imaging at 1, 6, and
12 mo of follow-up. At 1 mo may capture
early GCIPL thinning; early pRNFL measures
will reflect edema more than atrophy. Also,
capture total macular volume, and
automated retinal layer segmentation
outcomes. Adhere to OSCAR-IB criteria68
and APOSTEL recommendations127
Obtain spectral domain imaging at baseline
and semiannual or annual follow-up visits,
capturing pRNFL, total macular volume, and
automated retinal layer segmentation
outcomes. Account for history of and new
events of ON during study, as well as baseline







May provide baseline and follow-up
information about acute inflammatory activity,
but more broad use of measures across brain
structures may be more appropriate.
Obtain at visual nadir and final follow-up
visit. Recommend to consider using these
as predictors to response to therapy and
final functional visual outcome measures.
Obtain at baseline and final follow-up visit.
Recommend to consider using these as
predictors to response to therapy and final
functional and structural visual outcome
measures.
Visual QOL Should be included with other PROs in
secondary analyses.
Obtain at visual nadir and final study visit.
Recommend to include in all of these
studies as secondary outcome.
Obtain at baseline and final study visit.
Recommend to include in all of these
studies as secondary outcome.
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reported in progressive MS compared with both relapsing-
remittingMS and healthy controls.6 Notably, the INL exhibits
a complex spectrum of abnormalities in MS including
microcystoid macular pathology, increased thickness in as-
sociation with inflammatory disease activity, reduction in
thickness following DMT initiation, and atrophy in late,
progressive disease.e2-e4
OCT has also been used to support the identification of
clinical and subclinical ON by identifying intereye differences
in the pRNFL and GCIPL layers.44,e46-e47 OCT has also been
used for participant selection criteria to identify those who
may be more likely to benefit from remyelination therapies.19
A special consideration for MOGAD trials is the relative
preserved central acuity despite moderate to severe retinal
injury. Compared with NMOSD, for a given level of pRNFL
thinning, there are better HCVA outcomes in MOGAD.38
This may be due to less involvement of the papillomacular
bundle in MOGAD, but definitive studies are needed.
OCT outcomes have been studied in the pediatric population.
As in the adult MS population, decreased RNFL and GCIPL
are noted early in the disease course43,45 with evidence for
progressive RNFL and GCIPL loss through time. Thus, de-
spite having better visual function recovery, children have
similar burden of retinal thinning.43,45 As in adult patients,
distinct OCT patterns can distinguish pediatric neuro-
inflammatory disorders such as MOG-IgG– and AQP4-
IgG–related neuroinflammation from MS.e48
MRI Visual System Structural Measures
Complementary to OCT, MRI outcomes evaluate anterior
and posterior afferent visual pathway injury. Methodological
advances have overcome the challenges of optic nerve imag-
ing posed by its small size, mobility, and location adjacent to
nasal cavities, orbital fat, and CSF.e49 Particularly inMOGAD,
optic nerve MRI can speed diagnosis—showing characteristic
features including anterior longitudinal extensive optic nerve
lesions and perineural or periorbital gadolinium enhance-
ment.e50-e52
Optic nerve cross-sectional area can be reliably assessed using
a short-echo fast fluid-attenuated inversion recovery sequence
with fat and CSF suppression.e53 In a 12-month acute ON
longitudinal study of this method, there was an 11.7% greater
decline in affected vs unaffected optic nerve volumes.46 Optic
nerve atrophy correlated with RNFL thinning47 after ON, and
with both HCVA and P100 latency in chronic optic neuro-
pathye49, supporting potential use of this approach in trials
(Table 1).
Diffusion tensor imaging (DTI) captures three-dimensional
magnitude and direction of water diffusion. After acute ON,
diffusion parallel to axons (axial diffusivity, AD) is low,
whereas diffusion perpendicular to the axon, or radial diffu-
sivity (RD), remains in a normal range.48 In a 12-month
longitudinal study of 37 patients with acute ON,49 reduced
AD at baseline correlated with pRNFL thinning and mfVEP
amplitude loss at 6 and 12 months. Importantly, early re-
ductions in AD also predict VA recovery at 6 months,49,e54
suggesting that acute ON therapies that normalize optic nerve
AD could also promote axon survival and improve visual
outcomes. Baseline measurements of optic nerve DTI
(Table 2) may also help select patients who are most likely to
benefit from intervention.50 DTI can be obtained on most
commercial scanners but, unfortunately, adds significant ac-
quisition time and cost. Advanced image processing and an-
alytical requirements are additional barriers to widespread
implementation, but we anticipate reduction of these barriers
with improved, standardized software.
Application of optic nerve DTI in acute NMOSD-ON has not
been as well studied. In 1 retrospective study of 57 patients
with NMOSD-ON,e55 a radiomics model using whole-brain
DTI measures correlated strongly with visual outcomes after
IV methylprednisolone, suggesting its potential as a predictor
of response to acute therapy.
The magnetization transfer ratio (MTR) indicates the
balance between protons bound to molecules (protein and
lipids) vs free protons. Postmortem studies have confirmed
a strong association between a reduced MTR and demye-
lination,e56 whereas others have shown a similar correlation
between MTR and axonal density or both.e57 It is accepted
that a higher MTR indicates more bound protons, as seen
in normal, myelinated tissue. MTR decreases in acute
ONe58 with an approximate 8-month nadir46 and correlates
with P100 latency, HCVA,46 mfVEP amplitude, and RNFL
thinning.e59,e60 MTR in the optic nerve, whole brain, or T2
lesions have been used in clinical trials (Table 2, Table e1, links.
lww.com/NXI/A675). Timing and location of MTR mea-
surement in relation to the acute injury is critical for in-
terpretation of results. In the anti–LINGO-1 RRMS trial,
baseline lesional MTR was associated with disability outcomes
in the 10 mg/kg group.50
New Structural Biomarkers
OCT advances may offer novel biomarkers for future tri-
als.e61-e62 New machine learning retinal segmentation algo-
rithms decrease rater dependence, improve reliability, and
allow automatic quantification of disease-specific changes such
as microcystic macular edema.e63 Novel 3D methods resample
standardOCT images to depict retinal shape changes,e40,e64-e65
which may be especially useful to standardize assessment of
NMOSD foveal morphology changes.e40,e42,e66
Another new addition, OCT angiography (OCTA), uses the
movement of erythrocytes to create maps of the superficial
and deep retinal vascular plexuses and to calculate retinal
vascular flow rates. In MS and NMOSD, vessel reduction in
OCTA images is correlated with neuroaxonal damage, and in
MS, also with general disability (EDSS).51,e67-e68 Relative
blood flow velocity is decreased around the optic nerve head
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and fovea in patients with MS and AQP4-IgG–seropositive
ON.52,53
Finally, new MRI sequences such as double-inversion recovery
sequences can help detect early optic nerve injury and improve
timely trial inclusion.e69 Atlas-based automated segmentation
and volumetry of the LGN may facilitate understanding of




Assessments in Clinical Trials
With the increasing use of afferent visual assessments, it is
important to understand the best methods in a specific study
design and the main challenges and pitfalls in applying them
(Tables 3 and 4).
Study Design
Balancing the needs of generalizability vs risks of heteroge-
neity impairing detection of treatment effects, clinical trials
should clearly define the disease state measured (e.g., acute
optic neuritis and chronic optic neuropathy), inclusion and
exclusion criteria, and measurement protocols. Depending on
the intervention’s mechanism of action, different time points
or assessments should be considered; these decisions can be
critical to the success of the trial.
It is important to take into account differential pathophysio-
logic features of MS, NMOSD, and MOGAD as well as to
consider aging effects and potential basement effects (e.g.,
testing putative neuroprotective therapies in eyes with severe
optic neuropathy), and disease- or treatment-related retinal
changes such as microcystoid and/or fingolimod-associated
macular edema.e5,e70
Other important considerations are excluding patients with
confounding primary ophthalmologic pathologies (e.g., se-
vere myopia, glaucoma, central serous retinopathy, or diabetic
retinopathy) and identifying the up to 16% of patients with
MS who may have unrelated morphologic macular abnor-
malities such as drusen or epiretinal membranes, which can
induce OCT segmentation errors or be associated with
nonneurologic causes of visual dysfunction.e71
In ON, conduction block and inflammatory edema may limit
the use of standard VEP and pRNFL OCT measurements at
early time points. For chronic optic neuropathy, pathologic
sensitivity of some measures may change in the setting of
gliosise72 or visual repair (e.g., functional neuroplasticity).e9
Importantly, regulatory authorities are likely to always prefer a
clinical outcome for phase III RCTs, and trial duration of up
to 12 months may be needed to fully capture the effects of an
intervention on visual recovery.12
Advanced imaging techniques may provide the means to
better stratify and select trial participants most likely to benefit
from early intervention with a potential neuroprotective
therapy. Optic nerve DTI measurements such as AD, espe-
cially if assessed outside the anatomical segment with acute
inflammatory change, could more directly assess the degree of
axonal involvement. Similarly, MTR could also potentially be
used as an early stratification tool when allocating patients to
different treatment groups.e73
Data Acquisition
A strong study protocol defines the specific device(s), mea-
surement parameters, required environment (e.g., illumina-
tion and noise level), and patient needs (e.g., refractive
correction). Frequency of assessments needs to be tailored to
the clinical model (acute or chronic ON), temporal flux in
visual and paraclinical measures, and safety requirements. For
assessments requiring focus and alertness such as electro-
physiologic or VF perimetry, patients with fatigue or cognitive
dysfunction may require accommodations.54,e74 Efferent
dysfunction can negatively affect fixation and acquisition of
afferent measures. Severe acute ON can impair ability to fix-
ate, resulting in poor-quality electrophysiology and OCT
studies. Awareness of these pitfalls can help troubleshoot ways
to acquire the best data (e.g., fixate with the unaffected or less
affected eye during OCT acquisition).
Data Analysis
Ideally, multicenter trials should use identical devices and
protocols for data acquisition. When this is not feasible, the
statistical analysis plan should account for device and protocol
effects. Efforts to harmonize data from different OCT devices
are under way, and initial results are promising. Multisite
success has been demonstrated for automated retinal seg-
mentation software.55 In nonrandomized studies, multi-
variable modeling to account for confounding variables
(sex, age, ethnicity, history of ON, and baseline disability
measures) is important. Even in randomized studies,
tracking the ON status of each eye and considering ad-
justments for baseline values of measurements are important
as the meaning and magnitude of change in measures may
notably differ based on these variables, particularly for OCT
studies. In analyses for which each participant contributes data
from both eyes, intereye correlationsmust be adjusted for using
mixed-effects models or generalized estimating equations.
When possible, both eyes of a patient should be included, but
for correlations with MRI outcomes, either the best or worst
eye in terms of the outcome measure could be used. Averaging
values between eyes may result in losing information about
injury as the worse eye may be more informative about disease
injury than an averaged value. Eyes should be tested in-
dividually for HCVA and LCLA. If binocular measures are
included, the impact of the neuroimmunologic disease on
binocular summation/inhibition should be considered. In adult
MS, binocular summation may be impairede75 and could be an
outcome measure to consider if appropriate for the research
question.
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Quality Control and Reporting of OCT Results
Given the complexity of OCT technology, as well as its sus-
ceptibility to artifacts or confounding pathologies, complete
reporting of methodology and quality control are of paramount
importance. Investigators are recommended to adhere to the
OSCAR-IB criteria32 and APOSTEL recommendations56 for
quality control and reporting of OCT studies, respectively.
Efferent Visual System
and Oculometrics
Most people with MS experience efferent visual dysfunction
from disorders of fixation to intereye misalignment. Efferent
oculometric assessments may reveal deficits not readily appre-
ciated at bedside and associate with overall disability inMS.57 An
eye-tracking paradigm was able to detect subtle cerebellar dys-
function in participants without ataxia.58 Even in the very young,
with pediatric onset MS and no discernible disability on exam-
ination, saccadic latencies can distinguish eyes of patients with
MS from those of healthy controls.59 For rapidly quantifying
disease burden largely driven by the brainstem and cerebellum
(key contributors to overall disability scores), eye-tracking ap-
proaches offer objective, reliable means to collect these data.
Despite the great promise of efferent oculometric techniques
in quantifying neuroimmunologic disease burden, these ap-
proaches have not percolated significantly into clinical trials.
One interventional neuromodulation study lists video nys-
tagmography as an exploratory outcome of treatment efficacy
(NCT02252666). A primary reasonmay be the variety of eye-
tracking devices and software and a lack of widely accepted
protocol parameters for data quality. However, these are
surmountable obstacles, and similar consensus and quality
approaches could be applied as has been done for the afferent
measurements highlighted here.








Design the cohort as homogenously as possible and appropriate for the research question
Clearly specify the study population (RMS vs PMS, AQP4-IgG– vs MOG-IgG–positive disorders).
Exclude patients with certain systemic comorbidities and diagnoses that could influence outcomemeasures such
as severe myopia, CSR, glaucoma, or diabetic retinopathy.
Depending on your research question, consider excluding patients with disease- or treatment-related retinal
pathologies that could bias/influence your results such as microcystic macular edema, fingolimod-associated
macular edema, prior ON, or optic radiation lesions.
Simplified protocols for multicenter
studies
Be as specific as possible about device(s) needed,measurement parameters, and environment (e.g., illumination,




Consider the impact of other disease-related symptoms such as cognitive changes and fatigue on obtaining data,
and if this affects the quality of the study, consider excluding patients with specific symptoms.
Interference of vision-related
symptoms
If possible, use newest generation devices that may help mitigate other vision- and disease-related symptoms
interfering with the patient’s fixation abilities or functional measurements such as Pulfrich and Uhthoff
phenomenon, binocular summation, or sex-specific disease characteristics.
Interference of data quality OCT results are biased by low signal strength or cyclotorsion and other measurement artifacts (e.g., nystagmus-
induced motion artifact), and a premature classification of VEP latencies as absent can significantly decrease the
usability of the data.
pRNFL edema confounding atrophy
measurements
The pRNFL thickness in OCT can be dramatically affected by edema (thickened) during the acute stage of ON and
cannot be used as a marker of retinal neurodegeneration until >3–6 mo post-AON. The combined GCIPL layer is
less likely to be confounded by edema in early measurements.
Confounding of longitudinal
measurements by aging or
development of ocular diseases
To ensure correct longitudinal assessments, many devices allow to measure in a follow-up mode. However,
multiple influencing factors such as age andmyopia and learning effects have to be considered when comparing
longitudinal data to a normative cohort.
Data analysis
Increased error of point estimates
from combining data from
multicenter and multidevice studies
For most OCT and electrophysiologic assessments, the data from different devices and/or protocols are not yet
comparable. Advanced analysis approaches have to be applied to allow a merged data analysis.
Reliability and reproducibility across
centers
The intertest and intratest variability vary dramatically between centers and device operators. Ideally, the range
of variability should be established for each center, and (significant) results that are within the range of retest
variability should be interpreted with caution.
Abbreviations: RMS = relapsing MS; PPMS = primary progressive MS; MOG = myelin oligodendrocyte protein; AQP4 = aquaporin-4 channel; ON = optic
neuritis; OCT = optical coherence tomography; VEP = visual evoked potential; CSR = central serous retinopathy; pRNFL = peripapillary retinal nerve fiber layer.
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Advantages of Assessments in the
Visual System
Low Cost and Correlations With Other
Outcome Measures—Atrophy, Cognition, and
Employment Status
RNFL and GCIPL thinning on OCT are low-cost measures
that have shown considerable cross-sectional and longitudinal
associations with other outcomemeasures of tissue damage in
MS, including brain volume loss,39,e76-e77 in particular when
ON eyes are removed from analyses.e78-e79 These associations
likely emerge from a common pathophysiologic denominator
and suggest that in some settings, retinal measures may be
used as surrogates of MRI measures. Anterograde or retro-
grade transsynaptic degeneration involving retrogeniculate
parts of the visual pathway may influence these associa-
tions.e80-e81 Retinal damage may also relate to functional
connectivity changes in the visual system and other networks
in ON, MS, and NMOSD.e82-e84
RNFL and GCIPL thinning have been associated with worse
cognitive performance,e85-e86 suggesting a shared underlying
pathobiology of diffuse CNS tissue destruction. However,
reduced visual function might affect cognitive test perfor-
mance, and cognitive dysfunction may alter the capability to
execute more demanding visual tests such as LCLA testing.e74
Finally, higher serum neurofilament light chain (NfL) has
been associated with lower RNFL and GCIPL thickness val-
ues in the non-ON eyes of participants with MS.e87
Precision and in Vivo Human Microstructural/
Sensitive Functional Assessments
Unparalleled in the Other Systems Affected
by MS
The availability of sensitive measures has enabled rigorous
measurement of structural and functional changes in the in-
jured visual system to a greater degree than is possible in other
regions of the CNS.e88 Structural changes on OCT are
strongly correlated with changes in LCLA and visual QOL.
One can estimate the functional consequence of a 5–10-μm
change in RNFL thickness. Such precision has not been
clearly recorded for the corticospinal tracts, for example.
IMSVISUAL View of the Landscape
and Proposed Role of Visual System
for Trials of Agents in the Pipeline
IMSVISUAL aims to improve care, research, and education in
MS and other neuroinflammatory disorders by advancing our
understanding of the visual system and by providing a frame-
work and international standards for applying vision tools in
clinical trials. These methods are sensitive, reliable, and cost-
effective with strong structure-function correlations. Different
tools provide complementary information and have ideal time
points for use along the temporal course of visual injury
(Table 4). Best practices and even published standard criteria
exist to guide rigorous study design in visual outcome appli-
cations. For all paradigms of trials in MS and NMOSD (and
future trials inMOGAD), from standardDMT trials or those of
neuroprotection and remyelination, and even trials of com-
parative efficacy, applicationse90-e94 of visual outcome tools
offer cost-effectivemechanisms to capturewidespread and focal
injury across disease subtypes and may lead to more rapid
development of new therapeutics for these disabling diseases.
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